Biotechnology News and Research

RSS

Molecular genetics expert wins Wolf Prize for his contribution to humanity

Joachim Messing, among the world's top experts in molecular genetics, became famous for developing a genetic engineering technique used in laboratories to create plants that have produced disease-resistant crops considered vital to feeding the world's population.

30 Jan 2013

State roundup: Fla. leaders pay less for coverage than workers

In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.

30 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel ADCs for the treatment of cancer.

30 Jan 2013

Health industry shows stock market muscle

Despite various concerns and challenges, health care stocks, including shares of for-profit hospitals, have fared well in the opening weeks of 2013.

29 Jan 2013

Mary Ann Liebert to launch new LGBT Health journal

Over 4 million adults in the United States identify as gay, lesbian, or bisexual and approximately 700,000 identify as transgender. An NIH-sponsored investigation by the Institute of Medicine (IOM) concluded that the health status and healthcare needs of this sizable population are poorly understood and likely inadequately met. A journal is urgently needed to support, promote, and address the unique healthcare needs of each population that comprises the LGBT community, in the United States and worldwide.

29 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

Endo Pharmaceuticals, GVK BIO enter research collaboration agreement

GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein.

28 Jan 2013

Transcat acquires Cal-Matrix

Transcat, Inc., a leading distributor of professional grade handheld test, measurement and control instruments and accredited provider of calibration, repair, inspection and other compliance services, announced today that it has acquired Cal-Matrix Metrology Inc., a leading Canadian provider of commercial and accredited calibrations and coordinate measurement inspection services.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Viewpoints: A 'gift' to Amgen; Obama omits talk of grand bargain; Defending physician pay

For a disheartening example of how intense lobbying and financial contributions can distort the legislative process in Washington, consider what happened to the "fiscal cliff" bill approved three weeks ago by Congress.

23 Jan 2013

Amgen drug gets boost in fiscal cliff legislation

Just two weeks after pleading guilty in a major federal fraud case, Amgen, the world's largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the "fiscal cliff" bill that did not mention the company by name but strongly favored one of its drugs.

23 Jan 2013

Cytos announces Novartis termination from NIC002 smoking cessation project

Cytos Biotechnology Ltd today announced that Novartis will discontinue the NIC002 project, which is a therapeutic vaccine candidate for the treatment of nicotine addiction.

23 Jan 2013

SV Bio, Mayo Clinic partner on whole genome diagnostics and interpretation

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories.

23 Jan 2013

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

22 Jan 2013

Rainbow Coral visits genome-mapping facility in Houston

Since the new year began, Rainbow Coral Corp. has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Company's executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner.

22 Jan 2013

Biotechnology News and Research

Molecular genetics expert wins Wolf Prize for his contribution to humanity

State roundup: Fla. leaders pay less for coverage than workers

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

Health industry shows stock market muscle

Mary Ann Liebert to launch new LGBT Health journal

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Endo Pharmaceuticals, GVK BIO enter research collaboration agreement

Transcat acquires Cal-Matrix

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Viewpoints: A 'gift' to Amgen; Obama omits talk of grand bargain; Defending physician pay

Amgen drug gets boost in fiscal cliff legislation

Cytos announces Novartis termination from NIC002 smoking cessation project

SV Bio, Mayo Clinic partner on whole genome diagnostics and interpretation

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Rainbow Coral visits genome-mapping facility in Houston

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News